Use of Famotidine and Risk of Severe Course of Illness in Patients With COVID-19

Effectiveness of famotidine on the risk of poor prognosis in patients with COVID-19: A nationwide cohort study in Korea

“…After famotidine emerged as an option for the treatment of COVID-19, 7 research on the correlation between famotidine use and clinical outcomes was conducted in various centers. Although some retrospective, single-center, PSM studies showed famotidine treatment significantly reduced the risk of poor COVID-19 related outcomes in patients with COVID-19, retrospective multicenter studies and a meta-analysis showed no correlation between famotidine use and poor COVID-19 related outcomes [ [11] , [12] , [13] , [14] , [15] , [16] , [17] ]. In the most recent randomized clinical trial of patients with COVID-19 with mild to moderate symptoms, patients in the high-dose famotidine use group had to earlier resolution of symptoms and inflammation than other patients.…”

“…The propensity score-matched retrospective, single-center cohort studies found that famotidine use significantly reduces the risks of mortality and intubation in patients with COVID-19 [ 11 , 12 ]. However, a retrospective multi-center study and meta-analysis showed no correlation between famotidine use and poor COVID-19 related outcomes [ [13] , [14] , [15] , [16] , [17] ].…”

Famotidina en el tratamiento de pacientes hospitalizados con COVID-19. Revisión sistemática y metaanálisis

“…Kow y cols., en una carta al editor decidieron realizar un metaanálisis en base a la creciente fama de famotidina como un fármaco para el tratamiento de COVID-19 21 . Se basaron en el artículo publicado por Ghosh donde se discute la actividad de regulación en la respuesta inmune adaptativa 22 .…”

“…El resultado del metaanálisis de dos estudios reveló asociación no significante entre famotidina y el riesgo de progresión de la enfermedad (OR 0,85, IC 95% 0,27-2,63). Sin embargo, es un metaanálisis pequeño y carece de poder adecuado para generalizar una conclusión 21 .…”